NASDAQ:VRTX Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis $513.26 -1.37 (-0.27%) Closing price 04:00 PM EasternExtended Trading$513.00 -0.26 (-0.05%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vertex Pharmaceuticals Stock (NASDAQ:VRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vertex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$511.35▼$517.9550-Day Range$470.72▼$557.9652-Week Range$374.17▼$560.25Volume638,064 shsAverage Volume1.40 million shsMarket Capitalization$130.27 billionP/E Ratio29.88Dividend YieldN/APrice Target$570.83Consensus RatingModerate Buy Company Overview Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development. Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets. These medicines are designed to address the underlying cause of cystic fibrosis for eligible patients with specific genetic mutations. The company has expanded beyond cystic fibrosis through its collaboration with CRISPR Therapeutics on Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia. Vertex also markets Journavx, a non-opioid treatment for moderate to severe acute pain, and continues to develop potential therapies for conditions including type 1 diabetes and kidney disease. Vertex serves patients through commercial operations and partnerships across North America, Europe and other international markets. Reshma Kewalramani has served as the company’s president and chief executive officer since 2017.AI Generated. May Contain Errors. Read More Vertex Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreVRTX MarketRank™: Vertex Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 218th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingVertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 20 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialVertex Pharmaceuticals has a consensus price target of $570.83, representing about 11.3% upside from its current price of $512.94.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vertex Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.12% Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 9.12% in the coming year, from $16.88 to $18.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 29.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 29.86, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.06.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 2.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vertex Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.84% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 4.51.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently increased by 12.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.66 News SentimentVertex Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Vertex Pharmaceuticals this week, compared to 10 articles on an average week.Search InterestOnly 33 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows33 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,346,247.00 in company stock.Percentage Held by Insiders0.20% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vertex Pharmaceuticals' insider trading history. Receive VRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRTX Stock News HeadlinesVera Makes A Bullish Move — Times Three. Will It Hold Up To Competition?September 15 at 6:21 PM | msn.comWill Vertex’s (VRTX) New CFO Elevation and Digital Focus Reframe Its Capital Allocation Narrative?September 15 at 6:21 PM | finance.yahoo.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.September 16 at 1:00 AM | Porter & Company (Ad)Vertex Pharmaceuticals (VRTX), Why Is It Getting Fresh Attention Now?September 15 at 6:21 PM | finance.yahoo.comVera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?September 15 at 1:20 PM | finance.yahoo.comVertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute PainSeptember 15 at 8:18 AM | finance.yahoo.comVertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 11:00 AM | seekingalpha.comAmgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?September 14 at 7:15 AM | fool.comSee More Headlines VRTX Stock Analysis - Frequently Asked Questions How have VRTX shares performed this year? Vertex Pharmaceuticals' stock was trading at $453.36 on January 1st, 2026. Since then, VRTX stock has increased by 13.1% and is now trading at $512.9370. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Monday, August, 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts' consensus estimates of $4.74 by $0.01. The company's revenue for the quarter was up 12.5% compared to the same quarter last year. Read the conference call transcript. Does Vertex Pharmaceuticals have any subsidiaries? Vertex Pharmaceuticals subsidiaries include V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others. Who are Vertex Pharmaceuticals' major shareholders? Top institutional shareholders of Vertex Pharmaceuticals include BlackRock Inc. (9.50%), Wellington Management Group LLP (1.28%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.22%) and Bank of America Corp DE (1.20%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, David Altshuler, Joy Liu, Edward Morrow Atkinson III, Carmen Bozic, Jonathan Biller, Duncan Mckechnie, Mark E Bunnage, Kristen Ambrose and Sangeeta N Bhatia. View institutional ownership trends. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), Qualcomm (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/03/2026Today9/16/2026Bank of America Global Healthcare Conference9/23/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VRTX's financial health is in the Green zone, according to TradeSmith. VRTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VRTX CIK875320 Webwww.vrtx.com Phone(617) 341-6100Fax617-576-2109Employees6,400Year Founded1989Price Target and Rating Average Price Target for Vertex Pharmaceuticals$570.83 High Price Target$665.00 Low Price Target$442.00 Potential Upside/Downside+11.2%Consensus RatingModerate Buy Rating Score (0-4)2.96 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)$17.18 Trailing P/E Ratio29.88 Forward P/E Ratio30.41 P/E Growth2.25Net Income$3.95 billion Net Margins35.00% Pretax Margin41.90% Return on Equity23.09% Return on Assets16.72% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio2.74 Sales & Book Value Annual Sales$12.00 billion Price / Sales10.85 Cash Flow$17.36 per share Price / Cash Flow29.56 Book Value$73.57 per share Price / Book6.98Miscellaneous Outstanding Shares253,800,000Free Float253,297,000Market Cap$130.27 billion OptionableOptionable Beta0.32 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:VRTX) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredTSM just handed Trump's secretive AI project $100 billion — See this before September 29Taiwan Semiconductor just pledged another $100 billion to US chip manufacturing, bringing its total US investm...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
